An international study led by Matthew Harms, MD, and David Goldstein, MD, theĀ Genomic Translation for ALS Care (GTAC) study is following 1,500 people living with ALS over a three-year period to collect clinical data, sequence their DNA, and store blood samples to generate induced pluripotent stem cells (iPSCs). The correlation of this clinical and genetic information will help to stratify patients for future clinical trials. Ultimately, it will provide a basis for the development of precision medicine, or more individually tailored therapies for ALS. The GTAC study is unusual in that it is designed to return genetic findings to its participants, for their benefit and that of their family.